Cargando…
Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant BA.2 has spread in many countries, replacing the earlier Omicron subvariant BA.1 and other variants. Here, using a cell culture infection assay, we quantified the intrinsic sensitivity of BA.2 and BA.1 compared with...
Autores principales: | Ohashi, Hirofumi, Hishiki, Takayuki, Akazawa, Daisuke, Kim, Kwang Su, Woo, Joohyeon, Shionoya, Kaho, Tsuchimoto, Kana, Iwanami, Shoya, Moriyama, Saya, Kinoshita, Hitomi, Yamada, Souichi, Kuroda, Yudai, Yamamoto, Tsukasa, Kishida, Noriko, Watanabe, Shinji, Hasegawa, Hideki, Ebihara, Hideki, Suzuki, Tadaki, Maeda, Ken, Fukushi, Shuetsu, Takahashi, Yoshimasa, Iwami, Shingo, Watashi, Koichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9251960/ https://www.ncbi.nlm.nih.gov/pubmed/35798223 http://dx.doi.org/10.1016/j.antiviral.2022.105372 |
Ejemplares similares
-
Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants
por: Takashita, Emi, et al.
Publicado: (2022) -
Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75
por: Takashita, Emi, et al.
Publicado: (2022) -
Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro
por: Shionoya, Kaho, et al.
Publicado: (2021) -
Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants
por: Seki, Yohei, et al.
Publicado: (2022) -
Potential Anti-Mpox Virus Activity of Atovaquone, Mefloquine, and Molnupiravir, and Their Potential Use as Treatments
por: Akazawa, Daisuke, et al.
Publicado: (2023)